Progression-Free Survival After 12 Months for Medulloblastoma Subgroup Distribution
Medulloblastoma
DISEASE, MEDULLOBLASTOMA
The shaded areas represent 95% CIs; vertical dashed lines indicate the 12-month, 36-month, and 60-month time points; and crosses represent censored participants. MEMMAT indicates Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial; SHH, sonic hedgehog signaling molecule; and WNT, wingless-related integration site.In an exploratory analysis of patients who had disease control at 6 months, median PFS was 31.6 months (range, 11.0-52.2 months), and 5-year mean (SD) PFS was 42.8 (12.4) months. In the 18 patients (45.0%) who demonstrated any response (NED, CR, or PR), median PFS was 31.6 months (range, 11.0-52.2 months) and mean (SD) 5-year PFS was 49.7 (14.3) months. In the 13 patients (32.5%) who had no progression after 12 months of treatment, mean (SD) 5-year PFS rate was 66.7% (16.1%). Fifteen patients remained alive for a mean of 39 months (range, 12-95 months) after initiation of MEMMAT treatment, 12 of whom were progression free (eFigures 4-6 in 